Benzinga | Sep 14, 2021 08:02AM EDT

Medicenna Doses First Patient In MDNA11 Phase 1/2 ABILITY Study

-- Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors



-- Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021

-- Preliminary efficacy readouts from study expected over the course of 2022